Compare TCRT & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRT | SNOA |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.1M |
| IPO Year | N/A | 2007 |
| Metric | TCRT | SNOA |
|---|---|---|
| Price | $2.45 | $3.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.3K | 12.9K |
| Earning Date | 11-14-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,000.00 | ★ $16,937,000.00 |
| Revenue This Year | $5,680,500.00 | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.02 |
| 52 Week Low | $1.31 | $1.75 |
| 52 Week High | $6.20 | $6.92 |
| Indicator | TCRT | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 29.76 |
| Support Level | $2.60 | $3.28 |
| Resistance Level | $3.02 | $3.57 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 10.43 | 0.00 |
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.